We regret to report that long term Heidelberg Pharma AG (ETR:HPHA) shareholders have had that experience, with the share price dropping 40% in three years, versus a market decline of about 4.2%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback